An analysis of published patent applications in chimeric antigen receptor (CAR) T-cell immunotherapy allows insight into the development of this emerging technology.
Subscribe to Journal
Get full journal access for 1 year
only $20.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kolata, G. New gene-therapy treatments will carry whopping price tags. The New York Times https://www.nytimes.com/2017/09/11/health/cost-gene-therapy-drugs.html (11 September 2017).
Grady, D. Companies rush to develop ‘utterly transformative’ gene therapies. The New York Times https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html (23 July 2017).
Sadelain, M. & Rivière, I. CAR T cells in cancer therapy (poster). Nat. Rev. Drug Disc. (December 2017).
Golstein, P. & Griffiths, G. M. Nat. Rev. Immunol. 18, 527–535 (2018).
Mullard, A. Nat. Rev. Drug Discov. 14, 301 (2015).
Morrison, C. Nat. Biotechnol. 33, 571–572 (2015).
Dolgin, E. Nat. Biotechnol. 35, 891–892 (2017).
Trippe, A. Guidelines for Preparing Patent Landscape Reports (World Intellectual Property Organization, 2015).
Zuniga, P. et al. OECD Patent Statistics Manual (OECD, 2009).
European IPR Helpdesk. E-IPR fact sheet: automatic patent analysis. https://www.iprhelpdesk.eu/sites/default/files/newsdocuments/Fact-Sheet-Automatic-Patent-Analysis.pdf (2013).
Jürgens, B. & Herrero-Solana, V. J. Intell. Stud. Bus. 7, 17–26 (2017).
Dara, A. & Sangamwar, A. T. PLoS One 9, e103847 (2014).
Pan, C. L. & Chen, F. C. Hum. Vaccin. Immunother. 13, 2583–2593 (2017).
Anaya, M., Perez-Santos, M. & Muñoz-Rojas, J. Intl. J. Cancer Biol. Clin. Oncol. 1, 14–18 (2017).
Anonymous. Nat. Biotechnol. 35, 215 (2017).
Bouchie, A., Allison, M., Webb, S. & DeFrancesco, L. Nat. Biotechnol. 32, 229–238 (2014).
Bouchie, A. & DeFrancesco, L. Nat. Biotechnol. 33, 247–255 (2015).
Morrison, C. Nat. Biotechnol. 36, 131–136 (2018).
Yeager, A.J. CAR-T in the courts. Genetic Engineering News (11 September 2017).
This article is based on a study that was commissioned by the European Patent Office with the aim of demonstrating to readers outside the disciplines of patent analysis and CAR T-cell immunotherapy how patent information can be used to gain insight and competitive advantages about a specific technological field. The authors thank F. Aslund, P. Bumb and D. Manu from the European Patent Office for their support in the classification identification process and assistance for fine-tuning the search strategy. The opinions expressed in this article are those of the authors and not necessarily those of their employers.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Jürgens, B., Clarke, N.S. Evolution of CAR T-cell immunotherapy in terms of patenting activity. Nat Biotechnol 37, 370–375 (2019). https://doi.org/10.1038/s41587-019-0083-5
Bone Marrow Transplantation (2020)
Biomarker Research (2020)
World Patent Information (2020)
Applied Sciences (2019)